Marius Bredell1, Tamara Rordorf2, Sabine Kroiss3, Martin Rücker4, Daniel Fritz Zweifel5, Claudio Rostetter6. 1. Private Practice and Visiting Consultant, Cantonal Hospital Winterthur, Winterthur, Switzerland. Electronic address: marius.bredell@gesicht.ch. 2. Consultant, Department of Oncology, University Hospital of Zurich, Zurich, Switzerland. 3. Consultant, Department of Oncology, University Children's Hospital Zurich, Zurich, Switzerland. 4. Professor and Head of Department, Department of Craniomaxillofacial and Oral Surgery, University Hospital of Zurich, Zurich, Switzerland. 5. Consultant, Department of Craniomaxillofacial and Oral Surgery, University Hospital of Zurich, Zurich, Switzerland. 6. Resident, Department of Craniomaxillofacial and Oral Surgery, University Hospital of Zurich, Zurich, Switzerland.
Abstract
PURPOSE: Giant cell granuloma (GCG) of the jaw is a rare disease with high morbidity. Various treatment options have been discussed in the past. Since 2010, a pharmaceutical therapy with denosumab seems to have been successful for giant cell tumors of the femur. The authors hypothesized the equally successful use of denosumab for GCGs of the jaws. MATERIALS AND METHODS: In the present retrospective cohort study, 5 patients with large GCGs of the jaws were treated with denosumab with a follow-up of 25 to 49 months. Frequent clinical follow-ups and a radiologic follow-up were performed and systematically analyzed. RESULTS: All patients showed a curative treatment response and complete metabolic resolution of the GCGs under treatment with denosumab. CONCLUSION: A brief review of the relevant literature and a detailed evaluation of current cases led to the conclusion that denosumab therapy should be considered a therapeutic option for large central GCGs of the jaws. The results of this study suggest denosumab is a successful treatment option. A treatment length no shorter than 12 months is recommended and monitoring of treatment response can be well managed by positron-emission tomographic computed tomography or magnetic resonance imaging.
PURPOSE: Giant cell granuloma (GCG) of the jaw is a rare disease with high morbidity. Various treatment options have been discussed in the past. Since 2010, a pharmaceutical therapy with denosumab seems to have been successful for giant cell tumors of the femur. The authors hypothesized the equally successful use of denosumab for GCGs of the jaws. MATERIALS AND METHODS: In the present retrospective cohort study, 5 patients with large GCGs of the jaws were treated with denosumab with a follow-up of 25 to 49 months. Frequent clinical follow-ups and a radiologic follow-up were performed and systematically analyzed. RESULTS: All patients showed a curative treatment response and complete metabolic resolution of the GCGs under treatment with denosumab. CONCLUSION: A brief review of the relevant literature and a detailed evaluation of current cases led to the conclusion that denosumab therapy should be considered a therapeutic option for large central GCGs of the jaws. The results of this study suggest denosumab is a successful treatment option. A treatment length no shorter than 12 months is recommended and monitoring of treatment response can be well managed by positron-emission tomographic computed tomography or magnetic resonance imaging.
Authors: Yoon Ji Jina Rhou; Che-Jen Wang; Minh Nguyen; Joel A Vanderniet; Craig F Munns; Hedley Coleman; James Kim; Deborah Jane Holmes-Walker; Lydia Lim; Christian M Girgis Journal: Calcif Tissue Int Date: 2022-01-28 Impact factor: 4.333
Authors: Eelis Rytkönen; Vuokko Ottavainen; Aleksi Rytkönen; Sanna Uusitalo; Petri Lehenkari; George K Sándor Journal: Ann Maxillofac Surg Date: 2018 Jul-Dec
Authors: A Deodati; D Fintini; E Levtchenko; M Rossi; G Ubertini; H Segers; G Battafarano; M Cappa; A Del Fattore Journal: J Endocrinol Invest Date: 2021-07-03 Impact factor: 4.256
Authors: Carolina Cavalieri Gomes; Tenzin Gayden; Andrea Bajic; Osama F Harraz; Jonathan Pratt; Hamid Nikbakht; Eric Bareke; Marina Gonçalves Diniz; Wagner Henriques Castro; Pascal St-Onge; Daniel Sinnett; HyeRim Han; Barbara Rivera; Leonie G Mikael; Nicolas De Jay; Claudia L Kleinman; Elvis Terci Valera; Angelia V Bassenden; Albert M Berghuis; Jacek Majewski; Mark T Nelson; Ricardo Santiago Gomez; Nada Jabado Journal: Nat Commun Date: 2018-11-01 Impact factor: 14.919